...
首页> 外文期刊>Molecular cancer therapeutics >A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells.
【24h】

A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells.

机译:A6肽激活CD44粘附活性,诱导FAK和MEK磷酸化,并抑制CD44表达细胞的迁移和转移。

获取原文
获取原文并翻译 | 示例
           

摘要

The A6 peptide (acetyl-KPSSPPEE-amino) has antitumor activity in the absence of significant adverse events in murine tumor models and clinical trials. A6 shares sequence homology with CD44, an adhesion receptor involved in metastasis that is also a marker of cancer stem cells and drug-resistant phenotypes. We investigated the mechanism of action of A6 by examining its effects on CD44 activity, cell migration, and metastasis. A6 inhibited the migration of a subset of ovarian and breast cancer cell lines, exhibiting IC(50) values of 5 to 110 nmol/L. The ability of A6 to inhibit migration in vitro correlated with CD44 expression. Immunopreciptation studies showed that CD44 binds A6 and that biotin-tagged A6 can be cross-linked to CD44. The binding of A6 altered the structure of CD44 such that it was no longer recognized by a monoclonal antibody to a specific epitope. Importantly, A6 potentiated the CD44-dependent adhesion of cancer cells to hyaluronic acid and activated CD44-mediated signaling, as evidenced by focal adhesion kinase and MAP/ERK kinase phosphorylation. In vivo, A6 (100 mg/kg delivered s.c. twice daily) reduced the number of lung foci generated by the i.v. injection of B16-F10 melanoma cells by 50% (P = 0.029 in an unpaired t test). We conclude that A6 potently blocks the migration of CD44-positive cells in vitro through an interaction with CD44 that alters its structure and activates CD44 to enhance ligand binding and downstream signaling. The concurrent ability of A6 to agonize the CD44 receptor suggests that CD44 activation may represent a novel strategy for inhibiting metastatic disease.
机译:在鼠肿瘤模型和临床试验中,在没有明显不良事件的情况下,A6肽(乙酰基KPSSPPEE-氨基)具有抗肿瘤活性。 A6与CD44共享序列同源性,CD44是一种参与转移的粘附受体,也是癌症干细胞和耐药表型的标志。我们通过检查A6对CD44活性,细胞迁移和转移的作用,研究了A6的作用机理。 A6抑制卵巢和乳腺癌细胞系的一个子集的迁移,表现出5至110 nmol / L的IC(50)值。 A6在体外抑制迁移的能力与CD44表达相关。免疫沉淀研究表明CD44结合A6,生物素标记的A6可以与CD44交联。 A6的结合改变了CD44的结构,使得它不再被针对特定表位的单克隆抗体所识别。重要的是,A6增强了癌细胞对透明质酸的CD44依赖性粘附并激活了CD44介导的信号传导,如粘着斑激酶和MAP / ERK激酶的磷酸化所证明。在体内,A6(100 mg / kg每天两次皮下给药)减少了静脉注射产生的肺病灶数量。 50%注射B16-F10黑色素瘤细胞(未配对t检验中P = 0.029)。我们得出的结论是,A6通过与CD44相互作用(可改变其结构并激活CD44以增强配体结合和下游信号传导),在体外有效阻断CD44阳性细胞的迁移。 A6激动CD44受体的同时能力表明CD44激活可能代表抑制转移性疾病的新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号